Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City

February 7, 2018 • 4:30 PM EST

Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale

January 24, 2018 • 4:30 PM EST

Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

January 23, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture)

January 19, 2018 • 2:00 PM EST

Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer

January 9, 2018 • 7:00 AM EST

Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco

January 3, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease

December 12, 2017 • 7:00 AM EST

Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference

November 30, 2017 • 7:00 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update

November 7, 2017 • 7:00 AM EST

Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference

November 1, 2017 • 7:00 AM EDT

« Previous
1...
2
3
4
5
6
7
8
9
10
11
...28
Next »

Show All

News / Press Releases : Press Releases